These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 8524852)

  • 1. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Khodursky AB; Zechiedrich EL; Cozzarelli NR
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11801-5. PubMed ID: 8524852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials.
    Khodursky AB; Cozzarelli NR
    J Biol Chem; 1998 Oct; 273(42):27668-77. PubMed ID: 9765303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli.
    Zechiedrich EL; Khodursky AB; Cozzarelli NR
    Genes Dev; 1997 Oct; 11(19):2580-92. PubMed ID: 9334322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR; Malik M; Snyder M; Drlica K
    J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.
    Zechiedrich EL; Cozzarelli NR
    Genes Dev; 1995 Nov; 9(22):2859-69. PubMed ID: 7590259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of topoisomerase function in bacterial replication fork movement: use of DNA microarrays.
    Khodursky AB; Peter BJ; Schmid MB; DeRisi J; Botstein D; Brown PO; Cozzarelli NR
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9419-24. PubMed ID: 10944214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization.
    Hsu YH; Chung MW; Li TK
    Nucleic Acids Res; 2006; 34(10):3128-38. PubMed ID: 16757578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA.
    Aedo S; Tse-Dinh YC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5458-64. PubMed ID: 22869559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
    Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A
    Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.
    Hardy CD; Cozzarelli NR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):941-7. PubMed ID: 12604525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
    Bansal S; Tandon V
    Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting enzymatic activities of topoisomerase IV and DNA gyrase from Escherichia coli.
    Ullsperger C; Cozzarelli NR
    J Biol Chem; 1996 Dec; 271(49):31549-55. PubMed ID: 8940171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.
    Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3822-31. PubMed ID: 19564360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Drlica K; Zhao X
    Microbiol Mol Biol Rev; 1997 Sep; 61(3):377-92. PubMed ID: 9293187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
    Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of and resistance to ciprofloxacin.
    Hooper DC; Wolfson JS; Ng EY; Swartz MN
    Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of plasmid-mediated quinolone resistance.
    Tran JH; Jacoby GA
    Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of double strand DNA break repair for quinolone sensitivity in Escherichia coli: therapeutic implications].
    González-Soltero R; García-Cañas A; Mohedano RB; Mendoza-Chamizo B; Botello E
    Rev Esp Quimioter; 2015 Jun; 28(3):139-44. PubMed ID: 26032998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
    Deguchi T; Kikuchi M; Yasuda M; Ito S
    J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.